Since its founding in Carlsbad, California in 1995, biosyn Corporation has driven the development, manufacturing and marketing of hemocyanin and immunocyanin products forward. With German know-how, American ingenuity and the help of a California resident, the first hemocyanin product was approved in 1997. Ever since, biosyn has been the leading manufacturer of high-quality, clinical-, GMP- and research-grade hemocyanin products extracted from the Giant Keyhole Limpet. The anticancer drugs, immunotherapeutics and carrier-proteins for vaccines evolved from this combination benefit patients around the globe.
To learn more about Good Manufacturing Practice (GMP) at biosyncorp, visit biosyncorp.com/about-us/
What to do when the standard fails? Wasn't it enough that the patient suffered from superficial bladder cancer and now a post-TUR recurrence? After standard therapies were contraindicated, have been exhausted or were not tolerated in the first place, second-line treatment with IMMUCOTHEL® is indicated to prevent recurrences in superficial bladder cancer. This immunotherapeutic from biosyn is a safe, efficacious and well-established alternative to BCG. Thanks to its high tolerability and low rate of side effects, patients experience much less distress with IMMUCOTHEL®.